Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C182A, an Anti-Claudin18.2 CAR-T Cell Therapy in Patients With Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C182A, an Anti-Claudin18.2 CAR-T Cell Therapy in Patients With Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-Claudin 18.2 CAR-T cell therapy-First Affiliated Hospital Xi'an Jiaotong University (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Pancreatic ductal carcinoma
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Pharmacokinetics

    • Most Recent Events

    • 30 Jun 2020 Status changed from recruiting to discontinued.
    • 05 May 2019 Status changed from not yet recruiting to recruiting.
    • 02 Apr 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top